V
Vu Quoc Dat
Researcher at Hanoi Medical University
Publications - 26
Citations - 1889
Vu Quoc Dat is an academic researcher from Hanoi Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 23 publications receiving 792 citations. Previous affiliations of Vu Quoc Dat include University of Oxford.
Papers
More filters
Journal ArticleDOI
A minimal common outcome measure set for COVID-19 clinical research
John Marshall,Srinivas Murthy,Janet V. Diaz,Neil Adhikari,Derek C. Angus,Yaseen M. Arabi,Kenneth Baillie,Michael Bauer,Scott M. Berry,Bronagh Blackwood,Marc J. M. Bonten,Fernando A. Bozza,Frank M. Brunkhorst,Allen C. Cheng,Mike Clarke,Vu Quoc Dat,Menno de Jong,Justin T Denholm,Lennie P. G. Derde,Jake Dunning,Xiaobin Feng,Tom Fletcher,Tom Fletcher,Nadine E. Foster,Rob Fowler,Nina Gobat,Charles D. Gomersall,Anthony C. Gordon,Thomas Glueck,Michael O. Harhay,Carol L. Hodgson,Peter Horby,Yae Jean Kim,Richard Kojan,Bharath Kumar,John G. Laffey,Denis Malvey,Ignacio Martin-Loeches,Colin McArthur,Daniel F. McAuley,Stephen McBride,Shay McGuinness,Laura Merson,Susan C. Morpeth,Dale M. Needham,Mihai G. Netea,Mihai G. Netea,Myoung Don Oh,Sabai Phyu,Simone Piva,Ruijin Qiu,Halima Salisu-Kabara,Lei Shi,Naoki Shimizu,Jorge Sinclair,Steven Y. C. Tong,Alexis F. Turgeon,Timothy M. Uyeki,Frank L. van de Veerdonk,Steve Webb,Paula R Williamson,Timo Wolf,Junhua Zhang +62 more
TL;DR: A minimum set of common outcome measures for studies of COVID-19, which includes a measure of viral burden, patient survival, and patient progression through the health-care system by use of the WHO Clinical Progression Scale are urged.
Journal ArticleDOI
A living WHO guideline on drugs for covid-19
Bram Rochwerg,Arnav Agarwal,Reed A C Siemieniuk,Thomas Agoritsas,Francois Lamontagne,Lisa Askie,Lyubov Lytvyn,Yee Sin Leo,Helen Macdonald,Linan Zeng,Wagdy Amin,Erlina Burhan,Frédérique Jacquerioz Bausch,Carolyn S. Calfee,Maurizio Cecconi,Duncan Chanda,Bin Du,Heike Geduld,Patrick Gee,Nerina Harley,Madiha Hashimi,Beverly Hunt,Sushil K. Kabra,Seema Kanda,Leticia Kawano-Dourado,Yae-Jean Kim,Niranjan Kissoon,Arthur Kwizera,Imelda Mahaka,Hela Manai,Greta Mino,Emmanuel Nsutebu,Jacobus Preller,Natalia Pshenichnaya,Nida Qadir,Saniya Sabzwari,Rohit Sarin,Manu Shankar-Hari,Mike Sharland,Yinzhong Shen,Shalini Sri Ranganathan,João Paulo Souza,Miriam Stegemann,An De Sutter,Sebastian Ugarte,Sridhar Venkatapuram,Vu Quoc Dat,Dubula Vuyiseka,Ananda Wijewickrama,Brittany J. Maguire,Dena Zeraatkar,Jessica J Bartoszko,Long Ge,Long Ge,Romina Brignardello-Petersen,Andrew Owen,Gordon H. Guyatt,Janet V. Diaz,Michael Jacobs,Per Olav Vandvik +59 more
TL;DR: A standing international panel of content experts, patients, clinicians, and methodologists, free from relevant conflicts of interest, produce recommendations for clinical practice, containing a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic cortiosteroids for non-severe patients.
Journal ArticleDOI
A Systematic Review and Meta-analysis of Ventilator-associated Pneumonia in Adults in Asia: An Analysis of National Income Level on Incidence and Etiology.
Ana Bonell,Ryan Azarrafiy,Vu Thi Lan Huong,Thanh Le Viet,Vu Dinh Phu,Vu Quoc Dat,Heiman F. L. Wertheim,Heiman F. L. Wertheim,H. Rogier van Doorn,Sonia Lewycka,Behzad Nadjm +10 more
TL;DR: VAP remains a common cause of HAI, especially in low- and middle-income countries, and antibiotic resistance is high, and pooled rates and rates by country income level are given.
Journal ArticleDOI
Bacterial bloodstream infections in a tertiary infectious diseases hospital in Northern Vietnam: aetiology, drug resistance, and treatment outcome
Vu Quoc Dat,Vu Quoc Dat,Hieu Ngoc Vu,Hoa Thi Nguyen,Long Bao Hoang,Dung Vu Tien Viet,Chi Linh Bui,Kinh Van Nguyen,Trung Vu Nguyen,Dao Tuyet Trinh,Alessandro Torre,H. Rogier van Doorn,Behzad Nadjm,Heiman F. L. Wertheim +13 more
TL;DR: Enterobacteriaceae (predominantly K. pneumoniae and E. coli) are the most common cause of both community and hospital acquired bloodstream infections in a tertiary referral clinic in northern Vietnam.
Journal ArticleDOI
A living WHO guideline on drugs to prevent covid-19.
Francois Lamontagne,Thomas Agoritsas,Reed A C Siemieniuk,Bram Rochwerg,Jessica J Bartoszko,Lisa Askie,Helen Macdonald,Wagdy Amin,Frédérique Jacquerioz Bausch,Erlina Burhan,Maurizio Cecconi,Duncan Chanda,Vu Quoc Dat,Bin Du,Heike Geduld,Patrick Gee,Harley Nerina,Madiha Hashimi,Beverley J. Hunt,Sushil K. Kabra,Seema Kanda,Leticia Kawano-Dourado,Yae Jean Kim,Niranjan Kissoon,Arthur Kwizera,Yee Sin Leo,Imelda Mahaka,Hela Manai,Greta Mino,Emmanuel Nsutebu,Natalia Pshenichnaya,Nida Qadir,Shalini Sri Ranganathan,Saniya Sabzwari,Rohit Sarin,Mike Sharland,Yinzhong Shen,João Paulo Souza,Miriam Stegemann,Sebastian Ugarte,Sridhar Venkatapuram,Dubula Vuyiseka,Jacobus Preller,Romina Brignardello-Petersen,Elena Kum,Anila Qasim,Dena Zeraatkar,Andrew Owen,Gordon H. Guyatt,Lyubov Lytvyn,Janet V. Diaz,Per Olav Vandvik,Michael Jacobs +52 more
TL;DR: The first version of this living guideline focuses on the evidence for hydroxychloroquine as discussed by the authors, while subsequent updates will cover other drugs being investigated for their role in the prevention of covid-19.